8-K: ARS Pharma Faces Generic Challenge to Neffy Nasal Spray

ARS Pharmaceuticals received a Paragraph IV notice from Lupin Inc. for a generic version of its neffy epinephrine nasal spray, prompting a patent infringement defense.

Summary

• ARS Pharmaceuticals, Inc. received a Paragraph IV certification notice from Lupin Inc. on August 13, 2025.
• Lupin Inc. has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA), seeking approval to manufacture and sell a generic version of ARS Pharma's product neffy 2 mg (epinephrine nasal spray).
• Lupin alleges that eight U.S. Patents covering neffy, including a composition of matter patent (10,576,156) and one successfully defended against Inter Partes Review (10,682,414), are invalid, unenforceable, or will not be infringed.
• ARS Pharmaceuticals intends to vigorously defend its intellectual property rights relating to neffy and will promptly file a patent infringement suit against Lupin.
• Filing a lawsuit within 45 days of receiving the notice would trigger an automatic 30-month stay, preventing the FDA from granting final approval to Lupin's ANDA during that period.
• The company is currently unaware of any other ANDA filers for neffy as of the date of the filing.

Sentiment

Score: 3

Explanation: The filing indicates a significant challenge to the company's intellectual property and market exclusivity for its key product, neffy. While the company intends to defend its patents, the outcome is uncertain and introduces substantial risk and potential legal costs. The 30-month stay offers a temporary reprieve but does not resolve the underlying threat.

Positives

• The company intends to vigorously defend its intellectual property rights related to neffy.
• Filing a lawsuit within 45 days will trigger a 30-month stay, delaying potential generic market entry by Lupin.
• Currently, no other ANDA filers are known for neffy, suggesting a single generic challenge at this time.

Negatives

• Receipt of a Paragraph IV notice indicates a direct challenge to the market exclusivity of the company's key product, neffy.
• There is a potential for a generic version of neffy to enter the market prior to the expiration of the challenged patents, which could significantly impact future sales and revenue.
• The company will incur legal costs and resources to defend its patents against Lupin's challenge.
• There is no assurance as to the ultimate outcome of the ANDA submission and the impending patent infringement lawsuit, introducing significant uncertainty.

Risks

• If the FDA, the European Commission, or other comparable foreign regulatory authorities approve generic versions of neffy, or do not grant appropriate periods of non-patent exclusivity, the sales of neffy could be adversely affected.
• Risks related to the company's intellectual property, including the possibility that the challenged patents may be found invalid, unenforceable, or not infringed by Lupin's generic product.
• The ultimate outcome of the ANDA submission and the patent infringement lawsuit against Lupin is uncertain.

Future Outlook

The company intends to vigorously defend its intellectual property rights relating to neffy and promptly file a patent infringement suit against Lupin, seeking, among other remedies, a permanent injunction to prevent Lupin from introducing a generic version of neffy that would infringe the Patents. There can be no assurance as to the ultimate outcome of the ANDA submission and the lawsuit.

Management Comments

• We intend to vigorously defend our intellectual property rights relating to neffy.
• We will promptly file a patent infringement suit against Lupin, seeking, among other remedies, a permanent injunction to prevent Lupin from introducing a generic version of neffy that would infringe the Patents.

Industry Context

Generic challenges are a common occurrence in the pharmaceutical industry, where innovator companies rely heavily on patent protection for market exclusivity. A Paragraph IV certification indicates a generic manufacturer believes it can launch a product before the innovator's patents expire, often leading to costly and lengthy patent litigation. The 30-month stay provision is a standard mechanism designed to allow time for such litigation to proceed before a generic can enter the market, providing a temporary shield for the innovator.

Legal Proceedings

• ARS Pharmaceuticals, Inc. received a Paragraph IV certification notice from Lupin Inc. regarding a generic version of neffy.
• Lupin Inc. alleges that ARS Pharma's patents for neffy are invalid, unenforceable, and/or will not be infringed.
• ARS Pharmaceuticals intends to file a patent infringement suit against Lupin Inc. to defend its intellectual property rights.
• The lawsuit, if filed within 45 days, will trigger an automatic 30-month stay on FDA approval of Lupin's ANDA.

Stakeholder Impact

• Shareholders: Potential negative impact due to increased legal costs, uncertainty regarding future revenue from neffy, and potential loss of market exclusivity if the generic challenge is successful.
• Customers (Patients): Potential for a lower-cost generic alternative of epinephrine nasal spray to become available in the future, though delayed by the 30-month stay.
• Competitors: Lupin Inc. stands to gain market share if its generic ANDA is approved. Other potential generic manufacturers may be encouraged or deterred by the outcome of this litigation.

Next Steps

• ARS Pharmaceuticals intends to promptly file a patent infringement suit against Lupin Inc.
• The company will seek a permanent injunction to prevent Lupin from introducing a generic version of neffy that would infringe the Patents.

Key Dates

Recommendation

The receipt of a Paragraph IV notice for a key product like neffy represents a material adverse event for ARS Pharmaceuticals. While the company plans to defend its patents, the outcome of such litigation is inherently uncertain and can be lengthy and costly. The potential for a generic competitor to enter the market, even with a 30-month stay, introduces significant downside risk to future revenue and profitability. Investors should consider reducing exposure given the increased uncertainty and threat to the company's core asset.

Keywords

ARS Pharmaceuticals, neffy, epinephrine nasal spray, Lupin Inc., Paragraph IV, ANDA, generic drug, patent infringement, FDA, intellectual property, pharmaceuticals, SPRY